The Role of CXCL13 and CXCL9 in Early Breast Cancer.

Abstract

BACKGROUND:

Chemokines, cytokines in the immune microenvironment of tumors, may be associated with patient outcome. We assessed the impact of CXCL13 and CXCL9 on disease-free (DFS) and overall survival (OS), in an attempt to retrospectively evaluate both T and B cell function in the microenvironment of primary tumors from patients with breast cancer.

MATERIALS AND METHODS:

Formalin-fixed paraffin-embedded tissue blocks from patients with intermediate/high-risk, early breast cancer, treated with sequential adjuvant epirubicin, paclitaxel, and cyclophosphamide methotrexate fluorouracil within a randomized trial, were tested for CXCL13 and CXCL9 messenger RNA expression; 557 patients with adequate tissue were eligible for the analysis.

RESULTS:

CXCL13 was correlated with CXCL9 (rho = 0.52; P < .001). High-expressing CXL13 and CXCL9 tumors had higher Ki67 and tumor infiltrating lymphocyte density (P-values < .001). High CXCL9 expression was an unfavorable prognosticator for OS among all patients (hazard ratio [HR], 1.73; P = .021), whereas it showed favorable significance for both DFS and OS in patients with triple negative disease (HR, 0.29; P = .027 and HR, 0.32; P = .045). High CXCL13 conferred longer DFS and OS among patients with luminal-human epidermal growth factor receptor 2 disease (HR, 0.31; P = .013 and HR, 0.25; P = .005). Patients with low CXCL13 and high CXCL9 expression had shorter DFS and OS compared with those with high expression of both chemokines (HR, 1.63; P = .006 and HR, 1.61; P = .016).

CONCLUSIONS:

Both biomarkers were associated with poor prognosis characteristics and with tumor infiltrating lymphocyte density. High CXCL9 conferred an improved prognosis in the triple negative subtype, whereas high CXCL13 was associated with improved outcome in the luminal-human epidermal growth factor receptor 2 subtype. Chemokines can be associated with breast cancer subtype and outcome. These data should be evaluated prospectively.

• Authors: Evangelia Razis, Konstantine T Kalogeras, Ioannis Kotsantis, Georgia-Angeliki Koliou, Kyriaki Manousou, Ralph Wirtz, Elke Veltrup, Helen Patsea, Nikiforita Poulakaki, Dimitrios Dionysopoulos, Stavroula Pervana, Helen Gogas, Angelos Koutras, George Pentheroudakis, Christos Christodoulou, Helena Linardou, Kitty Pavlakis, Triantafyllia Koletsa, Dimitrios Pectasides, Flora Zagouri, George Fountzilas
• Journal: Clinical breast cancer (Clin Breast Cancer) Vol. 20 Issue 1 Pg. e36-e53 (02 2020) ISSN: 1938-0666 [Electronic] United States
• PMID: 31699671 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2019 Elsevier Inc. All rights reserved.

Chemical References

• Biomarkers, Tumor
• CXCL13 protein, human
• CXCL9 protein, human
• Chemokine CXCL13
• Chemokine CXCL9
• Receptors, Estrogen
• Receptors, Progesterone
• ERBB2 protein, human
• Receptor, ErbB-2

Topics

• Adult
• Aged
• Biomarkers, Tumor (analysis, metabolism)
• Breast (immunology, pathology, surgery)
• Breast Neoplasms (immunology, mortality, pathology, surgery)
• Chemokine CXCL13 (analysis, metabolism)
• Chemokine CXCL9 (analysis, metabolism)
• Disease-Free Survival
• Female
• Follow-Up Studies
• Gene Expression Profiling
• Humans
• Lymphocytes, Tumor-Infiltrating (immunology, metabolism)
• Mastectomy
• Middle Aged
• Prognosis
• Receptor, ErbB-2 (metabolism)
• Receptors, Estrogen (metabolism)
• Receptors, Progesterone (metabolism)
• Retrospective Studies
• Tissue Array Analysis
• Tumor Microenvironment (immunology)
• Young Adult